Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncANIX · Entity 6698 | Director | September 23, 2026 | September 25, 2026 |
| PARKERVISION INCPRKR · Entity 7682 | Director | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,046,003 |
Reported balance
After 2026-09-23 transaction · row 1
1 source rowRow 1 · 2026-09-23 · Purchase · Acquired 49,036 · Balance 1,046,003 |
PARKERVISION INC
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2031-01-22 | Direct | 370,000 |
Reported balance
After 2026-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 370,000 · Balance 370,000 F1: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 12:39 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 49,036 | $2.69 | $131,906.84 |
DisclosureSEC source: 0001493152-26-044250 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,046,003 Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 13:15 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001493152-26-042502 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 996,967 Read SEC document |
| July 20, 2026 Filed Jul 20, 2026 18:19 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 12,000 | $3.47 | $41,640.00 |
DisclosureSEC source: 0001493152-26-033949 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986,967 Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,797 | $3.28 | $9,174.16 |
DisclosureSEC source: 0001493152-26-033461 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 974,967 Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 11:21 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,836 | $2.64 | $7,487.04 |
DisclosureSEC source: 0001493152-26-029030 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 972,170 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 22:01 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantOption to Purchase Common Stock · Derivative | 370,000 | $0.24 Strike: $0.24 | $88,800.00 |
DisclosureSEC source: 0001437749-26-002107 · rdgdoc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,000 Underlying: Common Stock · 370,000 shares Expires 2031-01-22 F1 · derivative.exercise_date: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 19:44 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 25,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000689 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-01-05 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 08:56 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 16,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001493152-25-027904 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right-To-Buy, pursuant to a stock option grant dated February 18, 2016. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 08:56 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 16,000 | $2.92 | $46,720.00 |
DisclosureSEC source: 0001493152-25-027904 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 969,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 23:16 UTC | PARKERVISION INC PRKR · Entity 7682 | PurchaseCommon Stock | 4,761,905 | $0.21 | $1,000,000.05 |
DisclosureSEC source: 0001437749-25-035628 · rdgdoc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,578,170 F1 · kind: Reporting Person purchased 4,761,905 shares of ParkerVision common stock, $0.01 par value, for an aggregate purchase price of $1,000,000 or $0.21 per share, representing the last sale price of ParkerVision's common stock on November 14, 2025. The transaction closed on November 17, 2025. The offering was made pursuant to an existing shelf registration statement on Form S-3 that was declared effective by the SEC on May 28, 2025 (Registration No. 333-287427). The transaction was reviewed and approved by the disinterested directors of ParkerVision's board of directors in accordance with Section 607.0832 of the Florida Business Corporation Act. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:28 UTC | PARKERVISION INC PRKR · Entity 7682 | Exercise / conversionNonqualified Stock Option · Derivative | 275,000 | $0.20 Strike: $0.20 | $55,000.00 |
DisclosureSEC source: 0001437749-25-030658 · rdgdoc.xml · derivative · entry 4 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Optoin vested in four equal quarterly increments commencing May 1, 2024 and became fully exercisable February 1, 2025. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:28 UTC | PARKERVISION INC PRKR · Entity 7682 | Exercise / conversionNonqualified Stock Option · Derivative | 525,000 | $0.18 Strike: $0.18 | $94,500.00 |
DisclosureSEC source: 0001437749-25-030658 · rdgdoc.xml · derivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 525,000 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested in equal quarterly installments commencing January 27, 2024. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:28 UTC | PARKERVISION INC PRKR · Entity 7682 | Exercise / conversionCommon Stock | 275,000 | $0.20 | $55,000.00 |
DisclosureSEC source: 0001437749-25-030658 · rdgdoc.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,816,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 21:28 UTC | PARKERVISION INC PRKR · Entity 7682 | Exercise / conversionCommon Stock | 525,000 | $0.18 | $94,500.00 |
DisclosureSEC source: 0001437749-25-030658 · rdgdoc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,541,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $3.08 | $30,800.00 |
DisclosureSEC source: 0001641172-25-022000 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 953,334 Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 06:03 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $3.14 | $31,400.00 |
DisclosureSEC source: 0001641172-25-019587 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 943,334 Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:11 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantCommon stock | 275,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-022356 · rdgdoc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,153,765 F1 · price: Restricted Stock Units ("RSU") awarded as 2025 director compensation. Each RSU entitles holder to one share of the Company's common stock, $0.01 par value, upon vesting. RSU vests 50% upon grant and 50% on December 31, 2025. F2 · balance_after: Beneficial ownership, for purposes of this filing, includes 137,500 shares that will be issued upon vesting of the RSU on December 31, 2025. Read SEC document |
| May 06, 2025 Filed May 9, 2025 18:38 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionConvertible Note · Derivative | 1,699,844 | $0.13 Strike: $0.13 | $220,979.72 |
DisclosureSEC source: 0001641172-25-009406 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,699,844 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated May 10, 2022, as amended, with a face value of $200,000 and a fixed conversion price of $0.13. Read SEC document |
| May 06, 2025 Filed May 9, 2025 18:38 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionCommon Stock | 1,699,844 | $0.13 | $220,979.72 |
DisclosureSEC source: 0001641172-25-009406 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,878,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated May 10, 2022, as amended, with a face value of $200,000 and a fixed conversion price of $0.13. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 09:14 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 1,000 | $3.00 | $3,000.00 |
DisclosureSEC source: 0001493152-25-003733 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 933,334 Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 09:14 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,000 | $2.91 | $5,820.00 |
DisclosureSEC source: 0001493152-25-003733 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 932,334 Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 09:11 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,000 | $3.01 | $6,020.00 |
DisclosureSEC source: 0001493152-25-003330 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930,334 Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 09:13 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 6,000 | $2.59 | $15,540.00 |
DisclosureSEC source: 0001493152-25-003157 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 928,334 Read SEC document |
| January 17, 2025 Filed Jan 17, 2025 14:05 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $2.57 | $25,700.00 |
DisclosureSEC source: 0001493152-25-002717 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 922,334 Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:46 UTC | PARKERVISION INC PRKR · Entity 7682 | GiftCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000657 · rdgdoc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,178,921 Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 17:40 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 25,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001493152-25-000317 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-02 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2025. Read SEC document |
| December 31, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantCommon stock | 8,568 | $0.18 | $1,499.40 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,001,287 F5 · kind: Interest in kind paid on Convertible Notes dated June 19, 2019 and September 13, 2019. Read SEC document |
| December 31, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantCommon Stock | 29,413 | $0.17 | $5,000.21 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,992,719 F4 · kind: Interest in kind paid on Convertible Notes dated January 8, 2020 and May 10, 2022. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 11:27 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 16,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-24-042183 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right-To-Buy, pursuant to a stock option grant dated January 2, 2015. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 11:27 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 16,000 | $2.58 | $41,200.00 |
DisclosureSEC source: 0001493152-24-042183 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionConvertible Note · Derivative | 405,524 | $0.13 Strike: $0.13 | $52,718.12 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · derivative · entry 8 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 405,524 shares Expires 2025-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated January 8, 2020, as amended, with a face value of $50,000 and a fixed conversion price of $0.13. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionConvertible Note · Derivative | 514,740 | $0.10 Strike: $0.10 | $51,474.00 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · derivative · entry 7 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 514,740 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated September 13, 2019, as amended, with a face value of $50,000 and a fixed conversion price of $0.10. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionConvertible Note · Derivative | 257,370 | $0.10 Strike: $0.10 | $25,737.00 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · derivative · entry 6 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257,370 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated June 19, 2019, as amended, with a face value of $25,000 and a fixed conversion price of $0.10. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionCommon Stock | 405,524 | $0.13 | $52,718.12 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · nonDerivative · entry 5 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,178,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated January 8, 2020, as amended, with a face value of $50,000 and a fixed conversion price of $0.13. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionCommon Stock | 514,740 | $0.10 | $51,474.00 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · nonDerivative · entry 4 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,773,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated September 13, 2019, as amended, with a face value of $50,000 and a fixed conversion price of $0.10. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 23:13 UTC | PARKERVISION INC PRKR · Entity 7682 | ConversionCommon Stock | 257,370 | $0.10 | $25,737.00 |
DisclosureSEC source: 0001437749-24-030006 · rdgdoc.xml · nonDerivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,258,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares issued upon conversion of, and payment of accrued interest on, a Convertible Note dated June 19, 2019, as amended, with a face value of $25,000 and a fixed conversion price of $0.10. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 12:42 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,580 | $3.23 | $18,023.40 |
DisclosureSEC source: 0001493152-24-029884 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896,334 Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 12:42 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 21,646 | $3.06 | $66,236.76 |
DisclosureSEC source: 0001493152-24-029884 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 890,754 Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 06:05 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 7,700 | $3.03 | $23,331.00 |
DisclosureSEC source: 0001493152-24-029354 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 869,108 Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 06:05 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 796 | $2.81 | $2,236.76 |
DisclosureSEC source: 0001493152-24-029354 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 861,408 Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 09:22 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 4,000 | $2.68 | $10,720.00 |
DisclosureSEC source: 0001493152-24-024226 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 860,612 Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 09:56 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 405 | $2.70 | $1,093.50 |
DisclosureSEC source: 0001493152-24-023802 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,612 Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 11:18 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 7,102 | $2.66 | $18,891.32 |
DisclosureSEC source: 0001493152-24-023560 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,207 Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 11:18 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 330 | $2.60 | $858.00 |
DisclosureSEC source: 0001493152-24-023560 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 849,105 Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 10:03 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,738 | $2.52 | $27,059.76 |
DisclosureSEC source: 0001493152-24-023295 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 848,775 Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 09:44 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 15,009 | $3.28 | $49,229.52 |
DisclosureSEC source: 0001493152-24-014154 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838,037 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:04 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantOption to Purchase Common Stock · Derivative | 275,000 | $0.20 Strike: $0.20 | $55,000.00 |
DisclosureSEC source: 0001437749-24-003135 · rdgdoc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: Option was awarded as 2024 compensation for board and committee service and is exercisable in four equal quarterly increments beginning 5/1/2024. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 19:05 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001493152-24-002526 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-12 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2024. Read SEC document |
| December 19, 2023 Filed Feb 12, 2024 22:36 UTC | PARKERVISION INC PRKR · Entity 7682 | OtherCommon Stock | 9,375 | $0.16 | $1,500.00 |
DisclosureSEC source: 0001437749-24-003790 · rdgdoc.xml · nonDerivative · entry 5 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,963,306 F3 · kind: Reporting Person acquired shares of common stock as quarterly interest payments in-kind on a convertible note dated June 19, 2019 with a principal balance of $25,000 and a convertible note dated September 13, 2019 with a principal balance of $50,000. Read SEC document |
| November 18, 2023 Filed Nov 22, 2023 21:06 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantOption to Purchase Common Stock · Derivative | 600,000 | $0.18 Strike: $0.18 | $106,200.00 |
DisclosureSEC source: 0001437749-23-032893 · rdgdoc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-11-18 F1 · derivative.exercise_date: Option vests in eight equal quarterly increments beginning February 18, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.